Developmental Sensitivity in Schistosoma mansoni to Puromycin To Establish Drug Selection of Transgenic Schistosomes

Antimicrobial Agents and Chemotherapy
Hongbin YanGabriel Rinaldi

Abstract

Schistosomiasis is considered the most important disease caused by helminth parasites, in terms of morbidity and mortality. Tools to facilitate gain- and loss-of-function approaches can be expected to precipitate the discovery of novel interventions, and drug selection of transgenic schistosomes would facilitate the establishment of stable lines of engineered parasites. Sensitivity of developmental stages of schistosomes to the aminonucleoside antibiotic puromycin was investigated. For the schistosomulum and sporocyst stages, viability was quantified by fluorescence microscopy following dual staining with fluorescein diacetate and propidium iodine. By 6 days in culture, the 50% lethal concentration (LC50) for schistosomula was 19 μg/ml whereas the sporocysts were 45-fold more resilient. Puromycin potently inhibited the development of in vitro-laid eggs (LC50, 68 ng/ml) but was less effective against liver eggs (LC50, 387 μg/ml). Toxicity for adult stages was evaluated using the xCELLigence-based, real-time motility assay (xWORM), which revealed LC50s after 48 h of 4.9 and 17.3 μg/ml for male and female schistosomes, respectively. Also, schistosomula transduced with pseudotyped retrovirus encoding the puromycin resistance marker...Continue Reading

References

Feb 16, 2002·Methods : a Companion to Methods in Enzymology·K J Livak, T D Schmittgen
Mar 12, 2004·International Journal for Parasitology·Livia Pica-Mattoccia, Donato Cioli
Feb 9, 2005·Molecular Biotechnology·Sika Ristevski
Dec 1, 1959·Proceedings of the National Academy of Sciences of the United States of America·M B Yarmolinsky, G L Haba
May 29, 2007·Experimental Parasitology·Svenja BeckmannChristoph G Grevelding
Apr 3, 2008·The Journal of Clinical Investigation·Peter J HotezJulie Jacobson
Apr 12, 2008·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Kristine J KinesPaul J Brindley
Aug 30, 2008·Molecular and Biochemical Parasitology·Julie D ClarkDamer P Blake
Feb 19, 2009·BMC Microbiology·Alicia S LinfordWilliam A Petri
May 6, 2009·Development Genes and Evolution·Arnon D JurbergHenrique L Lenzi
May 26, 2009·Molecular and Biochemical Parasitology·Gabriel RinaldiPaul J Brindley
Jul 17, 2009·Nature·Matthew BerrimanNajib M El-Sayed
Sep 4, 2009·Journal of Chromatography. a·Daifeng JiangWilliam E Haskins
Sep 22, 2009·Parasitology·Victoria H MannPaul J Brindley
Nov 26, 2009·Brain Structure & Function·Miguel A Gama SosaGregory A Elder
Feb 4, 2010·PLoS Neglected Tropical Diseases·Kristine J KinesPaul J Brindley
Mar 27, 2010·Cellular and Molecular Life Sciences : CMLS·Elissaveta B TchoubrievaBernd H Kalinna
Aug 24, 2010·Nature Methods·Jennifer I SempleBen Lehner
Aug 24, 2010·Nature Methods·Rosina Giordano-SantiniDenis Dupuy
Sep 2, 2010·Nature Methods·Helen M Chamberlin
Mar 25, 2011·Cellular and Molecular Life Sciences : CMLS·Rosina Giordano-Santini, Denis Dupuy
Apr 7, 2011·Methods in Molecular Biology·Ning KeYama A Abassi
Aug 23, 2011·Parasitology·Sutas SuttiprapaPaul J Brindley
Sep 7, 2011·Parasitology·S Beckmann, C G Grevelding
Sep 14, 2011·PLoS Neglected Tropical Diseases·Victoria H MannPaul J Brindley
Dec 14, 2011·Annual Review of Entomology·Malcolm J Fraser
Dec 14, 2011·International Journal for Parasitology·Gabriel RinaldiPaul J Brindley
Jan 17, 2012·Nature Genetics·Neil D YoungRobin B Gasser
Jan 19, 2012·PLoS Neglected Tropical Diseases·Anna V ProtasioMatthew Berriman
Feb 1, 2012·Nature Methods·Jennifer I SempleBen Lehner
Feb 22, 2013·Nature·James J CollinsPhillip A Newmark

❮ Previous
Next ❯

Citations

May 28, 2019·The Journal of Venomous Animals and Toxins Including Tropical Diseases·Samanta Etel Treiger BorboremaNanci do Nascimento
Jun 18, 2021·Frontiers in Immunology·José T Moreira-FilhoCarolina H Andrade

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.